Cizzle Biotech
Cizzle Biotech is a UK-listed (LSE: CIZ) cancer diagnostics company commercializing the CIZ1B biomarker blood test for early-stage lung cancer detection via a proprietary two-step ELISA immunoassay, monetized primarily through regional licensing agreements with partners such as Cizzle Bio Inc in North America.
- Company typePublic
- Founded2021
- HeadquartersYork, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cizzle Biotech does
Cizzle Biotechnology Holdings plc is a UK-headquartered, London Stock Exchange-listed (LSE: CIZ) cancer diagnostics company commercializing the CIZ1B biomarker, a variant of the CIZ1 nuclear protein, for early-stage lung cancer detection. The company's sole product is the CIZ1B Biomarker Blood Test, a non-invasive immunoassay that uses a proprietary two-step sandwich ELISA format with monoclonal antibodies and a fibrinogen capture agent to detect CIZ1B in blood plasma, with the company reporting 95% sensitivity for early-stage disease. The technology was developed over two decades of grant-funded research led by Professor Dawn Coverley at the University of York, and is protected by patents granted in the United States, Canada, and Europe.
The company operates a licensing-based business model: it monetizes the test primarily through royalty-bearing regional licensing agreements rather than direct sales. In North America, Cizzle Bio Inc holds exclusive licensing rights (United States, Canada, Caribbean), with the first commercial deployment live at OmniHealth Diagnostics in Dallas, Texas following CLIA and COLA accreditation in June 2026. Cizzle receives a 10% royalty on gross sales of the test, plus guaranteed minimum royalty payments (US$2.4M due by end-2026 and a further US$3.5M from 2031). In November 2025, the company signed a Letter of Intent with a major UK laboratory provider serving the NHS, pointing toward a potential exclusive UK partnership aligned with the NHS National Cancer Plan target of 75% stage 1-2 diagnosis by 2028.
The company is pre-scale at the commercial level (11-50 employees, a single core product, and one operational commercial laboratory) and has funded operations through small, repeated capital raises and convertible notes since its 2021 IPO. Its growth thesis rests on expanding the licensed partner footprint (US, UK, Europe, China), building clinical evidence (Moffitt Cancer Center collaboration), and capturing share of the 14.2M-eligible US lung cancer screening population where only ~5.8-18.7% are currently screened.
Cizzle Biotech firmographics
Firmographics- Name
- Cizzle Biotech
- Legal name
- Cizzle Biotechnology Holdings plc
- Website
- https://cizzlebiotechnology.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cizzle Biotech is a UK-listed (LSE: CIZ) cancer diagnostics company commercializing the CIZ1B biomarker blood test for early-stage lung cancer detection via a proprietary two-step ELISA immunoassay, monetized primarily through regional licensing agreements with partners such as Cizzle Bio Inc in North America.
- Ownership category
- akta.pro rank
Cizzle Biotech industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Reference & Esoteric Testing Laboratories (HLAFAMAJ)
Keywords
Where Cizzle Biotech is headquartered
LocationHeadquarters
- HQ city
- York
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Cizzle Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others
Revenue model
- Licensing Royalties: Cizzle Biotech generates revenue through royalty-bearing licensing agreements with regional partners. The company receives 10% royalty on gross sales of the CIZ1B biomarker test. Additional guaranteed minimum royalty payments provide revenue certainty: US$2.4 million in guaranteed advance royalties due by end of 2026, plus an additional US$3.5 million in guaranteed minimum royalty payments (at least US$500,000 per year) commencing when the agreement is extended in 2031.
- Upfront and Milestone Payments: The company receives upfront payments and milestone payments from licensing partners. Initial payments include US$300,000 royalty payment received in October 2024, with additional payments tied to regulatory approvals, CLIA accreditation, and commercial launches.
- Research Collaborations: Revenue from research agreements with partners including the University of York, St George Street Capital, and others for development of cancer diagnostic technologies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Royalty-based licensing model with guaranteed minimum payments |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Cizzle Biotech product offering
Product offeringCore offering
Cizzle Biotech develops and licenses the CIZ1B Biomarker Blood Test, a non-invasive in-vitro diagnostic immunoassay that detects lung cancer at its earliest stages. The test uses a proprietary two-step sandwich ELISA format with a fibrinogen capture agent and proprietary monoclonal antibodies to identify the CIZ1B protein variant in blood plasma, achieving 95% sensitivity for early-stage lung cancer detection.
Product overview
Cizzle Biotech offers a single core product: the CIZ1B Biomarker Blood Test. This diagnostic test is designed for early-stage lung cancer detection and operates as a two-step ELISA immunoassay that identifies the CIZ1B protein variant in blood samples. The technology was developed at the University of York over two decades of research led by Professor Dawn Coverley. The test is licensed for commercialization in North America and the Caribbean through Cizzle Bio Inc., with patent protection secured in the US, Canada, and Europe. Commercial deployment began in 2026 following CLIA accreditation at OmniHealth Diagnostics in Dallas, Texas.
Differentiator
Problem solved
Functional benefit
Products and services
- CIZ1B Biomarker Blood Test A non-invasive, cost-effective in-vitro diagnostic blood test that detects lung cancer at its earliest stages using the proprietary CIZ1B protein biomarker measured via a two-step sandwich ELISA immunoassay with fibrinogen capture. The test demonstrates 95% sensitivity for early-stage lung cancer detection and is intended for use by licensed healthcare providers and clinical laboratories as a complement to low-dose CT screening, including for high-risk populations such as smokers, former smokers, and never-smokers.
Quantifiable outcome
- 95% sensitivity for early-stage lung cancer detection
- +3 more outcomes
Companies that use Cizzle Biotech
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Cizzle Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cizzle Biotech partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and minor.
- OmniHealth DiagnosticscoreCLIA-certified and COLA-accredited clinical laboratory in Dallas, Texas that achieved the first commercial deployment of the CIZ1B test in the United States. Part of the Katharos Health family of laboratories, offering comprehensive testing services including genetic testing, molecular diagnostics, and clinical laboratory testing.
- Major UK Laboratory ProviderflagshipLetter of Intent signed with a major UK laboratory provider serving the National Health Service, which may lead to an exclusive UK partnership and co-branded rollout across NHS and private markets in the UK.
- Moffitt Cancer CentercoreCollaboration to evaluate the CIZ1B biomarker in patients with suspicious lung nodules. This marks the first major clinical evaluation of the CIZ1B biomarker in a leading cancer center setting in the United States.
- BBI SolutionscoreManufacturing agreement for the CIZ1B biomarker test. BBI Solutions is a leading manufacturer of immunological reagents and assays supporting diagnostic development.
- Cizzle Bio IncflagshipExclusive licensing agreement for the CIZ1B biomarker test in the United States, Canada, and Caribbean. Cizzle Bio Inc is a Texas-based biotechnology company dedicated to advancing biomarker-based blood tests for early cancer detection. The partnership includes guaranteed royalty payments and milestone payments tied to regulatory and commercial achievements.
- Chinese Strategic Alliance PartnerminorStrategic alliance for early lung cancer detection in China, including clinical pilot study for early lung cancer detection.
- St George Street CapitalminorCompanion diagnostic supply agreement and royalty-bearing arrangement for AZD1656 diabetes therapy, separate from the CIZ1B lung cancer test.
- University of YorkcoreTwo decades of grant-funded research led by Professor Dawn Coverley at the University of York, where the CIZ1B protein variant was first identified and linked to early-stage lung cancer. Ongoing collaboration for innovation and new IP creation for the CIZ1B biomarker.
Scale indicators8 records
Recent moves3 records
Expansion highlights6 records
Cizzle Biotech competitors and assessment
Company assessmentDirect peers
- Oncimmune Holdings: UK-listed developer of the EarlyCDT Lung blood test for early-stage lung cancer detection using autoantibodies. Most direct global comparator to Cizzle given the same disease focus, blood-based biomarker approach, and UK public-company profile.
- GRAIL: US-based developer of the Galleri multi-cancer early-detection blood test using methylation-based ctDNA. Competes in the same blood-based early cancer detection category, targeting asymptomatic high-risk populations and payor channels.
- Biodesix: US lung-focused diagnostics company offering blood-based tests (e.g., Nodify XL2) for pulmonary nodule risk assessment and lung cancer treatment guidance. Direct competitor in the blood-test-for-lung-nodule decision pathway that Cizzle's CIZ1B also targets.
Broad incumbents
- Guardant Health: Leading US liquid biopsy company with blood-based oncology tests including Guardant360 and Reveal. Operates in adjacent cancer diagnostics with established clinical lab infrastructure and oncology channel relationships relevant to lung cancer screening and monitoring.
- Exact Sciences: US-listed diagnostics leader behind Cologuard and the Oncotype DX franchise. Relevant given its established blood-and-stool cancer screening commercial model, primary-care physician channel, and payor coverage capabilities that any successful lung cancer screening test must replicate.
- Natera: US molecular diagnostics company with Signatera MRD test and broader oncology blood-test menu. Comparable commercial model of selling tumor-informed blood tests through hospital and oncology channels relevant to lung cancer detection workflows.
- Veracyte: US genomic diagnostics company with pulmonary product lines (e.g., Percepta Genomic Sequencing Classifier) for lung nodule risk assessment. Competes in the lung cancer diagnostic workup space with an established commercial channel.
Emerging players
- Freenome: US-based multiomics blood testing company developing colorectal and other cancer screening assays. Emerging competitor in blood-based early-detection category with similar CLIA-lab commercialization strategy.
Regional players
- Singlera Genomics: China-based liquid biopsy company developing blood-based cancer detection tests including for lung cancer. Regional peer relevant given Cizzle's earlier Chinese strategic alliance and broader Asia licensing ambitions.
Others
- BBI Solutions: UK-headquartered manufacturer of immunological reagents and custom assay development services, already partnered with Cizzle for CIZ1B test manufacturing. Functions as a critical supplier rather than competitor but central to Cizzle's outsourced commercial model.
Market position
Strengths2 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Cizzle Biotech social profiles
Digital presenceCizzle Biotech compliance and trust
Trust signalCompliance2 records
Cizzle Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cizzle Biotech leadership team
Management profileNumber of profiles
Profiles4 records
Cizzle Biotech funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cizzle Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cizzle Biotech
What does Cizzle Biotech do?
Cizzle Biotech develops and licenses the CIZ1B Biomarker Blood Test, a non-invasive in-vitro diagnostic immunoassay that detects lung cancer at its earliest stages. The test uses a proprietary two-step sandwich ELISA format with a fibrinogen capture agent and proprietary monoclonal antibodies to identify the CIZ1B protein variant in blood plasma, achieving 95% sensitivity for early-stage lung cancer detection.
Is Cizzle Biotech a public or private company?
Cizzle Biotech is a public company. It is classified as public and is currently operating.
When was Cizzle Biotech founded?
Cizzle Biotech was founded in 2021. It employs 11 to 50 people.
Where is Cizzle Biotech based?
Cizzle Biotech is headquartered in York, United Kingdom, in the Europe region.
How does Cizzle Biotech make money?
Three revenue lines are on record. Licensing Royalties are the primary driver. The others are upfront and Milestone Payments and research Collaborations.
Who are Cizzle Biotech's main competitors?
Direct peers on record are Oncimmune Holdings, GRAIL and Biodesix. Broad incumbents are Guardant Health, Exact Sciences, Natera and Veracyte. Freenome is listed as an emerging player. Singlera Genomics is listed as a regional player. BBI Solutions is listed as an others.
Does Cizzle Biotech have an API?
No public API is recorded for Cizzle Biotech.
What industry is Cizzle Biotech in?
Cizzle Biotech's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 325413 and its SIC code is 2835.